| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00432-008-0524-X |
| P698 | PubMed publication ID | 19125300 |
| P2093 | author name string | Klaus Höffken | |
| Sebastian Scholl | |||
| Hans-Joerg Fricke | |||
| Herbert G Sayer | |||
| P2860 | cites work | Implications of NRAS mutations in AML: a study of 2502 patients | Q27824859 |
| Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). | Q27824861 | ||
| FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications | Q27851415 | ||
| Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients | Q27851417 | ||
| Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia | Q27851430 | ||
| Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study | Q27851436 | ||
| Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party | Q27851437 | ||
| High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients | Q28209409 | ||
| Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration | Q28263954 | ||
| MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia | Q28272533 | ||
| Proteomic analysis of human acute leukemia cells: insight into their classification | Q33208195 | ||
| Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications | Q33244998 | ||
| Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles | Q34098676 | ||
| Functional proteomic profiling of AML predicts response and survival | Q34184598 | ||
| Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia | Q34313643 | ||
| The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite | Q34517403 | ||
| Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis | Q34523534 | ||
| Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease | Q34524219 | ||
| No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. | Q34559865 | ||
| Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study | Q34570206 | ||
| MicroRNA expression in cytogenetically normal acute myeloid leukemia | Q34775265 | ||
| FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia | Q35792858 | ||
| The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy | Q35847845 | ||
| Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. | Q35989707 | ||
| High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CAL | Q36677320 | ||
| Immunotherapeutic targeting of Wilms' tumor protein. | Q36748263 | ||
| Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse | Q36835063 | ||
| Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. | Q36926841 | ||
| Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. | Q37086937 | ||
| Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study | Q37119445 | ||
| Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia | Q38301992 | ||
| Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study | Q38319029 | ||
| Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias | Q38347392 | ||
| A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells | Q40205794 | ||
| Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis | Q40325513 | ||
| Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia | Q81793636 | ||
| Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia | Q81919725 | ||
| BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia | Q24291902 | ||
| Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin | Q24652323 | ||
| MN1, a novel player in human AML | Q24653588 | ||
| Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies | Q27824769 | ||
| CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations | Q27824809 | ||
| Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype | Q27824827 | ||
| RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years | Q27824840 | ||
| Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations | Q27824843 | ||
| Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype | Q27824844 | ||
| Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study | Q27824856 | ||
| KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival | Q40357255 | ||
| AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. | Q40446315 | ||
| Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. | Q40821721 | ||
| Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias | Q43878422 | ||
| High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics | Q44034346 | ||
| Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit | Q44142819 | ||
| Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. | Q44189526 | ||
| Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol | Q44194162 | ||
| Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. | Q44401465 | ||
| BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study | Q44443179 | ||
| Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia | Q44449269 | ||
| Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples | Q44772618 | ||
| Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. | Q44826208 | ||
| Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. | Q44888876 | ||
| FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model | Q45271875 | ||
| Risk assessment in patients with acute myeloid leukemia and a normal karyotype | Q45299096 | ||
| Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis | Q46549470 | ||
| PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects | Q46724516 | ||
| Tipifarnib in acute myeloid leukemia | Q46823519 | ||
| BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications | Q48684574 | ||
| Prognostically useful gene-expression profiles in acute myeloid leukemia. | Q51999490 | ||
| Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). | Q52569827 | ||
| FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. | Q54008419 | ||
| Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. | Q54138925 | ||
| High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. | Q54546717 | ||
| Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. | Q54564116 | ||
| Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. | Q54613492 | ||
| Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. | Q54652934 | ||
| Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. | Q54655693 | ||
| The MLL recombinome of acute leukemias | Q56965972 | ||
| Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state | Q57006319 | ||
| Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia | Q57218620 | ||
| Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias | Q57734345 | ||
| Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group | Q58416097 | ||
| High Expression Levels of theETS-Related Gene,ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study | Q59315411 | ||
| FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia | Q64008554 | ||
| Internal tandem duplication of the flt3 gene found in acute myeloid leukemia | Q71841108 | ||
| Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations | Q72692051 | ||
| Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR | Q73446193 | ||
| Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse | Q74805736 | ||
| Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors | Q77145850 | ||
| Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay | Q77299371 | ||
| Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) | Q78290356 | ||
| Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia | Q79789394 | ||
| Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML | Q79803077 | ||
| Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations | Q79954785 | ||
| An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML | Q80794418 | ||
| Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia | Q81074303 | ||
| Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype | Q81712971 | ||
| P433 | issue | 4 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 491-505 | |
| P577 | publication date | 2009-01-06 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | Clinical implications of molecular genetic aberrations in acute myeloid leukemia | |
| P478 | volume | 135 |
| Q28282623 | Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease |
| Q33782633 | Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features |
| Q34764504 | Biology, risk stratification, and therapy of pediatric acute leukemias: an update |
| Q38341497 | Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes. |
| Q35627570 | CREB and leukemogenesis |
| Q39539195 | Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects |
| Q34004131 | Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia |
| Q35794120 | Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia |
| Q35788613 | Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype. |
| Q38963204 | Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype. |
| Q39450821 | Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia |
| Q35690315 | Prognostic significance of the BAALC gene expression in adult patients with acute myeloid leukemia: A meta-analysis |
| Q34285937 | Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia |
| Q36827373 | Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition |
| Q37422388 | The Role of miRNA in Haematological Malignancy. |
| Q48882411 | WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia |
Search more.